Description

ZEPZELCA (lurbinectedin)

For the treatment of metastatic small cell lung cancer

Important Safety Information

ZEPZELCA is a prescription medication used in specific clinical settings. It should only be administered under the supervision of a qualified healthcare professional experienced in cancer treatment.

---

Hero Section

ZEPZELCA (lurbinectedin)
A treatment option for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Developed to target transcription processes in cancer cells.

---

About ZEPZELCA

ZEPZELCA (lurbinectedin) is an alkylating agent that works by binding to DNA in cancer cells, disrupting transcription and ultimately leading to cancer cell death.

It is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have disease progression on or after platinum-based chemotherapy.

---

Indication

ZEPZELCA is indicated for:

• Adult patients with metastatic small cell lung cancer (SCLC)
• Disease progression following platinum-based chemotherapy

This indication is based on clinical studies evaluating tumor response in patients with relapsed SCLC.

---

Mechanism of Action

ZEPZELCA binds to the minor groove of DNA, where it interferes with active transcription processes.

This disruption:

• Inhibits oncogenic transcription programs
• Induces DNA damage
• Promotes cancer cell apoptosis (programmed cell death)

---

Administration

• Administered as an intravenous (IV) infusion
• Given in a clinical setting by a healthcare professional
• Dosing schedule is determined based on patient factors and clinical judgment

Patients should be monitored during and after infusion for potential adverse reactions.

---

Safety Information

ZEPZELCA may cause serious side effects, including:

• Myelosuppression (decreased blood cell counts)
• Neutropenia (low white blood cells)
• Hepatotoxicity (liver enzyme elevations)
• Fatigue
• Nausea and vomiting

Monitoring Requirements

Regular blood counts and liver function tests are recommended during treatment.

---

Common Side Effects

The most commonly reported side effects include:

• Fatigue
• Nausea
• Decreased appetite
• Muscle pain
• Constipation
• Decreased blood cell counts

---

Important Warnings

• ZEPZELCA should only be administered in a controlled medical environment
• Patients should be monitored for infection due to risk of low white blood cell counts
• Dose adjustments may be required based on tolerability

---

Patient Support & Resources

Patients and caregivers may have access to support programs designed to assist with:

• Treatment education
• Infusion scheduling
• Financial assistance information (where applicable)
• Side effect management resources

---

Healthcare Professional Information

For prescribing clinicians:

• Review full prescribing information before initiating therapy
• Assess baseline blood counts and liver function
• Monitor regularly throughout treatment cycles

---

Footer Disclaimer

ZEPZELCA is a prescription medicine. This content is intended for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.